非那雄胺对大鼠良性前列腺增生致下尿路症状的影响及作用机制

doi:10.3969/j.issn.1671-7171.2025.06.028

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1461 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect and mechanism of finasteride on lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) in rats. 【Methods】 Thirty rats were divided into sham operation group, model group, and finasteride group, with 10 rats in each group. The model group and finasteride group were used to establish BPH models by castration plus injection of testosterone propionate, while the sham operation group was not castrated and injected with an equal amount of sesame oil. After successful modeling, the finasteride group was intragastrically administered with finasteride at 0.8 mg/kg, and the model group and sham operation group were intragastrically administered with normal saline for 28 consecutive days. After the last gavage, the urination status of each group was detected; the rats were sacrificed to calculate the prostate index and bladder index. HE staining was used to observe the histopathological changes of prostate and bladder tissues, Masson staining to observe the collagen fiber deposition in bladder tissues, and TUNEL method to detect the apoptosis rate of bladder detrusor cells. Western blot was used to detect the relative expression levels of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), interleukin-1β (IL-1β), and cysteine-aspartic acid protease-1 (Caspase-1) in bladder detrusor. 【Results】Compared with the sham operation group, the prostate index, bladder index, micturition frequency, and residual urine volume in the model group were increased (P<0.05), while the total urine volume had no change (P>0.05). Compared with the model group, the prostate index, bladder index, micturition frequency, and residual urine volume in the finasteride group were decreased (P<0.05), and the total urine volume had no change (P>0.05). HE staining showed that the prostate tissue in the model group had obvious hyperplasia, the lamina propria connective tissue of the bladder tissue was hyperplastic, the mucosa was thickened, and a large number of bladder epithelial cells showed papillary hyperplasia; the histopathology of the prostate and bladder tissues in the finasteride group was significantly improved. Compared with the sham operation group, the apoptosis rate of bladder detrusor cells, the positive area ratio of collagen fibers, and the relative expression levels of NLRP3, IL-1β, and Caspase-1 proteins in bladder tissues in the model group were increased (P<0.05). Compared with the model group, the apoptosis rate of bladder detrusor cells, the positive area ratio of collagen fibers, and the relative expression levels of NLRP3, IL-1β, and Caspase-1 proteins in bladder tissues in the finasteride group were decreased (P<0.05). 【Conclusion】Finasteride can effectively improve LUTS caused by BPH in rats and inhibit the apoptosis of bladder detrusor cells, and its mechanism may be related to the NLRP3/Caspase-1 signaling pathway.

Key words： Prostatic Hyperplasia Androstenes Rats Disease Models, Animal Lower Urinary Tract Symptoms

Received: 14 February 2024

PACS:

R697.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEI Chao
	DING Yufeng

Cite this article:

WEI Chao,DING Yufeng. Effects and Mechanism of Finasteride on Lower Urinary Tract Symptoms Caused by Benign Prostatic Hyperplasia in Rats[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 1011-1014.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.06.028 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I6/1011

[1] 任宝明, 马龙, 闵晓明. 不同年龄前列腺增生患者下尿路症状的相关性分析[J].疑难病杂志, 2019, 18(2):167-169.
[2] MADERSBACHER S, SAMPSON N, CULIG Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review [J].Gerontology,2019, 65(5):458-464.
[3] YU Z J, YAN H L, XU F H, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia [J].Front Pharmacol,2020, 11:658.
[4] 王寅磊, 冯宝民, 卢轩, 等. 5-α还原酶抑制药用于治疗良性前列腺增生的研究现状[J].中国临床药理学杂志, 2019, 35(11):1217-1220.
[5] 王飘, 常雅卉, 赵思俊, 等. 建立良性前列腺增生动物模型的时间评定[J].中国药物与临床, 2019, 19(6):870-873.
[6] SILVA V, GRANDE A J, PECCIN M S. Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction [J].Cochrane Database Syst Rev,2019, 4(4):CD012044.
[7] MONREAL R, ROBLES C, SÁNCHEZ-CASADO M, et al.Embolisation of prostate arteries in benign prostatic hyperplasia in non-surgical patients [J].Radiologia (Engl Ed),2020, 62(3):205-212.
[8] GONCHAROVA N, CHIGAROVA O, RUDENKO N, et al. Glucocorticoid negative feedback in regulation of the hypothalamic-pituitary-adrenal axis in rhesus monkeys with various types of adaptive behavior: Individual and age-related differences [J].Front Endocrinol (Lausanne),2019, 10:24.
[9] 奚晓剑, 米华. aldh2基因表达对氯胺酮诱导的小鼠膀胱炎症及纤维化的影响[J].广西医科大学学报, 2020, 37(4):586-592.
[10] KITTA T, CHIBA H, KANNO Y, et al. Bladder outlet obstruction disrupts circadian bladder function in mice [J].Sci Rep,2020, 10(1):11578.
[11] DE NUNZIO C, SALONIA A, GACCI M, et al. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia [J].World J Urol,2020, 38(11):2771-2779.
[12] TOLANI M A, SULEIMAN A, AWAISU M, et al. Acute urinary tract infection in patients with underlying benign prostatic hyperplasia and prostate cancer [J].Pan Afr Med J,2020, 36:169.
[13] CHEN L, HE P L, YANG J, et al. NLRP3/IL1β inflammasome associated with the aging bladder triggers bladder dysfunction in female rats [J].Mol Med Rep,2019, 19(4):2960-2968.
[14] WULLT B, BUTLER D S C, AMBITE I, et al. Immunomodulation-A molecular solution to treating patients with severe bladder pain syndrome?[J].Eur Urol Open Sci,2021, 31:49-58.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 882-884.